Lifeboat Foundation

DEAR MAYO CLINIC: I’ve heard about several people who have experienced sudden cardiac arrest. What is cardiac arrest? And how is it different from a heart attack? What do you do for someone who has this condition?

ANSWER: Cardiac arrest, or sudden cardiac arrest as it is more formally known, is a medical emergency. Think of it as a problem with the heart’s electrical activity. This synchronized electrical activity allows the heart to fill and pump blood normally. Sudden cardiac arrest can happen unexpectedly and quickly, and the heart stops working. It’s not the same as a heart attack, but it is just as critical that treatment occurs rapidly.

Cardiac arrest is when the heart cannot fulfill its duties, such as pumping oxygenated blood around the body to reach critical areas such as the brain and the rest of the body. It is sometimes called “sudden” because it seems to happen without warning. A person suddenly loses all heart activity, stops breathing and becomes unconscious. Without immediate treatment, sudden cardiac arrest can lead to death.

Researchers at Uppsala university have developed a new method to find mutations in brain tumors in children. They also showed that the mutations change how cancer cells respond to a cancer drug. These findings could lead to better diagnostics and more individualized treatment of children with brain tumors. The study is published in the journal Proceedings of the National Academy of Sciences.

Medulloblastoma is the most common malignant brain tumor in children. It usually develops in the cerebellum and although modern treatment has improved the prognosis so that more than 70% of patients now live more than five years, not all patients can be cured. The aggressive cancer treatment also causes severe side effects such as balance problems and impaired learning abilities in cancer survivors.

Numerous studies have explored the less than 2% of human DNA that gives rise to proteins, and much less is known about the rest of the genome. In a cancer, such as medulloblastoma, 98% of the mutations thus occur in the less studied part of the genome. There could be thousands of mutations, and it is difficult to separate the ones driving the cancer from those without importance.

STING (short for stimulator of interferon genes) is considered one of the major factors that triggers the immune response in the context of infection, autoimmunity, and cancer. The signaling protein turns on genes involved in cell defense. Now, a team of MIT and Harvard Medical School researchers has discovered that STING can also act as an ion channel that allows protons to leak out of an organelle known as the Golgi body. This makes it the first human immune sensor that can translate danger signals into ion flow.

The findings are published in the journal Science in an article titled, “Human STING is a proton channel.”

“Proton leakage from organelles is a common signal for noncanonical light chain 3B (LC3B) lipidation and inflammasome activation, processes induced upon stimulator of interferon genes (STING) activation,” wrote the researchers. “On the basis of structural analysis, we hypothesized that human STING is a proton channel. Indeed, we found that STING activation induced a pH increase in the Golgi and that STING reconstituted in liposomes enabled transmembrane proton transport.”

A drug that causes animals to grow new teeth is heading to clinical trials. If it proves safe and effective in people, it could one day allow us to regenerate teeth lost to injury, disease, or old age.

The challenge: 17% of Americans will lose all of their teeth by the time they’re 65, and the vast majority of us will lose at least some teeth as we get older.

While dentures or implants can replace these lost teeth, one can feel less-than-natural, and the other requires surgery.

Cellular therapies like chimeric antigen receptor (CAR) T cells could represent a promising new avenue by which to treat autoimmune diseases, according to a recent review article. The authors cautioned, however, that most of the research testing CAR-based therapies has been in very early-stage trials.

CAR T cells are human cells that have been genetically modified to express a synthetic receptor, The cells have been used successfully as a therapy in several types of cancer, such as large B-cell lymphoma and multiple myeloma.

Manipulating T cells to target cancer cells has worked to treat some cancers. Researchers are investigating whether the same approach might be used to curb the dysregulated immune response that underlies autoimmune disease.

Continue reading “CAR T Cells Could Change the Face of Autoimmune Therapy” »

UK scientists have begun developing vaccines as an insurance against a new pandemic caused by an unknown “Disease X”.

The work is being carried out at the government’s high-security Porton Down laboratory complex in Wiltshire by a team of more than 200 scientists.

Year 2021 😗😁😘

The authors developed a vaccine against a membrane-bound seno-antigen called GPNMB and show that it can be used as a new senolytic approach. The vaccine led to improvements of several age-related phenotypes and prolonged the lifespan of a progeroid mouse model.

An important objective of medical research is to identify the underlying molecular mechanisms of human brain health and diseases.

This objective has been predominantly achieved through observational studies of gene expression in human brain tissues obtained from post-mortem brain donors for their analysis. Importantly, many of these studies are based on the assumption that gene expression in the post-mortem human brain is an exact representation of gene expression in the living human brain.

A recent study published on the medRxiv preprint server challenges this assumption by comparing human prefrontal cortex gene expression between living and post-mortem samples.

Malaria is a possibly fatal disease caused by a parasite transferred by mosquitos to humans. Common symptoms include fever, chills, and flu-like traits. According to the Centers for Disease Control (CDC), around 2,000 cases of malaria are diagnosed in the United States per year. The diagnosis is common in individuals coming back from Africa or Asia. On a global scale, about 700,000 people die from malaria, and most are children. However, death from malaria can usually be prevented with early detection and proper medical care. Researchers are trying to proactively target malaria by developing a new vaccine using genetic material.

Researchers from the Victoria University of Wellington’s Ferrier Research Institute, the Malaghan Institute of Medical Research, and the Peter Doherty Institute for Infection and Immunity have all worked together to develop a vaccine that can effectively stimulate cells in the immune system against malaria-causing parasite, Plasmodium. The vaccine, described in Nature Immunology, is designed to generate resident memory cells in the liver to combat Plasmodium. Resident memory cells are a type of immune cell that reside in tissues throughout the body to target invading pathogens that enter those tissues.

The vaccine is made with messenger ribonucleic acid (mRNA), as opposed to peptides or proteins. The difference between the two is the type of material delivered by the vaccine. Peptide-based vaccines use peptides from the virus to elicit an immune response. Alternatively, mRNA vaccines use mRNA extracted from the virus. In this study, the researchers originally used a peptide-based vaccine but recently found mRNA improves the activation of resident immune cells to kill malaria-based pathogens. The treatment result was significant between the two types of vaccines because the peptide-based vaccine had small fragments of protein and could not stimulate the immune system effectively, while the mRNA could encode for an entire malaria protein.